Scroll Top
About Respiri
Respiri Limited
(ASX:RSH, OTCQB:RSHUF)

Respiri Limited is uniquely positioned to revolutionise chronic disease management globally and is focused on the US market, where our suite of evidence-based programs qualify for Current Procedural Terminology (CPT) Code reimbursement. Respiri’s unique medical device when integrated into data-driven programs and enhanced with our clinical expertise ensure patients’ healthcare needs are delivered across the continuum of care. Programs such as Remote Patient Monitoring and Chronic Care Management empower healthcare organisations to act on patient data when needed, not only during scheduled appointments to improve patient outcomes.

We support our customers to maximise value with a range of customisable programs which meet the health journey needs of patients for all CMS-approved CPT codes, offering providers an opportunity to drive reduced medical events, improved patient health outcomes and reduced healthcare costs while prioritising revenue creation and reimbursement.

For details on our US programs visit www.respiri.co/us

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians.
For details on our US offerings, including wheezo®, visit www.respiri.co/us/wheezo

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.
wheezo® is a registered trademark of Respiri Limited

The Executive team

Respiri boasts a world class team consisting of a highly respected Chief Executive Office with a career spanning the healthcare industry, providing valuable experience in medical devices, pharmaceuticals, information systems, technology and sleep disorder solutions. A General Manager of Commercial Operations leading the Commercialisation Team bringing extensive experience in health, successful launches and building teams. An experienced Chief Clinical Officer leading Respiri’s algorithm development and clinical content, and a Chief Technical Officer, with Silicon Valley pedigree, leading the build of the app and data management infrastructure.

The entire team is the driving force behind the new SaaS strategy.

The Board
Nicholas Smedley
Executive Chairman
Mr Smedley is an experienced Investment Banker and M&A Advisor, with 14 years’ experience at UBS and KPMG. He has worked on M&A transactions in the UK, Hong Kong, China, and Australia with transactions ranging from the A$9bn defence of WMC Resources through to the investment of $65m into Catch.com.au. Nicholas currently oversees investments in the Property, Aged care, Technology and Medical Technology space. Key areas of expertise include M&A, Debt structuring, Corporate governance and innovation. He holds a Bachelor of Commerce from Monash University.
Nicholas-Smedley
Marjan Mikel
Chief Executive Officer

Marjan has been at the helm of Respiri taking it from R&D to commercialisation since 2019. A highly experienced managing director and board member with a career spanning Australia, Europe, Japan and the US, Marjan’s focus has been in the healthcare industry; from pharmaceuticals and information services and technology to medical devices and sleep disorder solutions. He founded and subsequently sold Healthy Sleep Solutions after developing it into a successful business, with ResMed Ltd as a joint venture/shareholder partner.

Currently, Marjan also acts as commercial advisor to Portt, a SaaS company, and is an industry research fellow at University of New South Wales Faculty of Engineering.

Qualifications: BSc (Hons), University of Sydney, Grad Dip Ed, Secondary Education, University of Sydney, MCom Masters of Commerce, University of New South Wales, MAICD, Business Administration, Management and Operations, AGSM, University of New South Wales

Respiri CEO named as one of Insightscare’s 2023 Top 10 Influential Healthcare Leaders in Australia.
Read more

Marjan Mikel
Brad Snow
Non-Executive Director

With 27 years of experience across MedTech, HIT & Biotech start-ups/emerging growth. Brad currently, serves as CEO, President and BOD of Angel-Medical, a start-up class III implantable cardiology company. Prior to Angel-Med, he served as CEO and BOD of SonaCare Medical (Sonablate Inc.) where he successfully led an exit.

Brad has extensive experience in Sales, Marketing, Operations and fundraising with an emphasis in turnarounds including but not limited to running 3/4 commercial divisions at BTGplc (acquired by Boston Scientific for $4.2B). Previously, Brad held sales and marketing leadership positions at Medlogics, ARAGON Surgical (Acquired B Braun), Fox Hollow Technologies (Acquired $750MM) and RITA Medical (Acquired $220MM).les-Fox Hollow Tech: Acquired $1.5B

Brad-Snow

You are about to leave this website.

Respiri LTD is not responsible for the content or policies on the linked website.

Do you wish to continue?